Phase III success with extended-release carbidopa–levodopa formulation

By Eleanor McDermid, Senior medwireNews Reporter

An extended-release formulation of carbidopa-levodopa reduces the amount of off-time in patients with Parkinson's disease, show results from a phase III randomized trial.

This results in apparent "clinically meaningful" improvements in motor function, report lead researcher Robert Hauser (University of South Florida, Tampa, USA) and co-workers. Furthermore, patients do not need to take their medication as often if given an extended-release formulation.

"These findings are exciting and reignite the long hope for improved levodopa delivery, despite previous disappointing experiences with other controlled-release formulations," says Olivier Rascol (University UPS of Toulouse III, France) in a commentary accompanying the paper in The Lancet Neurology.

The 471 patients recruited to the trial first underwent a 3-week period during which the investigators ascertained the optimal dose of immediate-release carbidopa-levodopa for each patient. This was followed by a 6-week dose-conversion phase during which the optimal dose of the immediate-release drug was used as a basis to determine the ideal dose of the extended-release formulation.

The 393 patients who completed these phases were randomly assigned to receive 13 weeks' treatment with either the immediate- or extended-release formulation. At study entry, these patients had an average daily off-time of 5.97 hours.

By the end of the randomized treatment period, this fell to 3.87 hours in the extended-release group compared with 4.88 hours in the immediate-release group, a significant difference. Off-time as a percentage of waking hours fell by 13.1% in the extended-release group versus 6.2% in the immediate-release group.

The average on-time without troublesome dyskinesia was significantly greater in patients taking the extended- versus immediate-release formulation by the end of the study, while on-time with troublesome dyskinesia did not differ between groups. The latter finding "suggests that levodopa peaks were not substantially increased and extended-release carbidopa-levodopa dosing was clinically appropriate," says the team.

Patients taking the extended-release formulation had significantly greater improvements on the Patient and the Clinical Global Impression of Change scales than those taking immediate-release carbidopa-levodopa. They also improved more on the Unified PD Rating Scale in both the on- and off-medication states.

The most common adverse events in the extended-release group were insomnia, nausea, and falls, while depression was most common in the immediate-release group.

In his commentary, Rascol notes that although extended-release carbidopa-levodopa may be a step forward, no matter how well patients respond to the drug, they will still experience levodopa-resistant symptoms and deteriorating function over time. "Improving the mode of delivery of carbidopa-levodopa will not change this fact."

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Discovery points toward a new strategy for treating Parkinson's disease